Trust Signals
Key Takeaways
- Proinsulin and c-peptide are both cleaved from the same precursor, but they answer different clinical questions: proinsulin reflects beta-cell processing stress, c-peptide reflects total secretory output.
- C-peptide has a half-life roughly 4 to 6 times longer than insulin and escapes hepatic first-pass clearance, making it a more reliable peripheral index of insulin secretion.
- A fasting proinsulin-to-insulin molar ratio above 0.2 is a sensitive early signal of beta-cell dysfunction that can precede changes in HbA1c by years, based on prospective cohort data.
- Stimulated c-peptide above 0.2 nmol/L is the threshold used in multiple type 1 diabetes trials to define clinically meaningful residual beta-cell function (used as an endpoint in TrialNet studies).
- Both assays have significant cross-reactivity and calibration problems; comparing a result across different laboratory platforms is unreliable without harmonized reference standards.
Direct Answer: Proinsulin vs C-Peptide
Table of Contents
- What are proinsulin and c-peptide, and how are they related biochemically?
- How does beta-cell processing work, with specific numbers?
- Evidence ledger: what each marker actually predicts
- When should you measure proinsulin vs c-peptide?
- Honest head-to-head comparison table
- What most pages get wrong about these two markers
- Why assay cross-reactivity changes your interpretation
- Operational and label literacy: reading a lab report correctly
- Frequently Asked Questions
- Sources
- Footer Disclaimers
What Are Proinsulin and C-Peptide, and How Are They Related Biochemically?
Both molecules originate from a single precursor. Beta cells in the islets of Langerhans translate preproinsulin, an 11.5 kDa single-chain precursor. After signal peptide cleavage in the endoplasmic reticulum, the resulting proinsulin (approximately 9 kDa, 86 amino acids in humans) folds into the correct three-dimensional structure held by three disulfide bonds. Inside secretory granules, two prohormone convertases (PC1/3 and PC2) and carboxypeptidase E cleave the central connecting segment: the 31-amino-acid c-peptide is released along with the mature two-chain insulin molecule (A-chain plus B-chain).
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Because one molecule of proinsulin yields exactly one molecule of c-peptide and one molecule of insulin, secretion is theoretically equimolar. C-peptide carries no known receptor-mediated metabolic action in the classical sense, though there is ongoing research into c-peptide signaling through GPR146 and other targets. Proinsulin itself has weak insulin-like bioactivity, estimated at roughly 3 to 5 percent of mature insulin potency.
How Does Beta-Cell Processing Work, With Specific Numbers?
Under normal fasting conditions, roughly 95 percent of what a healthy beta cell secretes is fully processed insulin. Intact proinsulin accounts for only 1 to 3 percent of total insulin immunoreactivity in fasting plasma in healthy adults, based on immunoassay studies using two-site monoclonal antibodies (data from Ward et al. and Haffner et al. in the early 1990s IRAS and MCSA cohorts). Split proinsulin intermediates (des-31,32 and des-64,65 forms) make up another small fraction.
When beta cells are stressed, whether by glucotoxicity, lipotoxicity, ER stress, or autoimmune attack, PC1/3 activity is reduced or granule transit time is shortened. The result is that incompletely processed proinsulin is secreted alongside mature insulin. The proinsulin-to-insulin molar ratio rises above the normal threshold of approximately 0.2. In established type 2 diabetes, intact proinsulin can represent 20 percent or more of total insulin immunoreactivity.
C-peptide pharmacokinetics: published half-life estimates range from roughly 20 to 31 minutes (compared to 3 to 5 minutes for insulin). The kidneys are the primary site of c-peptide degradation; hepatic extraction is less than 10 percent. This means peripheral c-peptide concentration reflects total portal insulin secretion far more faithfully than peripheral insulin itself, which undergoes 50 to 80 percent first-pass hepatic extraction.
Evidence Ledger: What Each Marker Actually Predicts
| Claim | Best evidence type | Effect direction | Confidence |
|---|---|---|---|
| Fasting c-peptide distinguishes type 1 from type 2 diabetes | Multiple prospective cohorts, cross-sectional studies (UKPD, TrialNet) | Low c-peptide = type 1; high/normal = type 2 | High |
| Stimulated c-peptide above 0.2 nmol/L predicts better glycemic control in type 1 | Prospective RCT substudies (TrialNet) | Positive: residual function improves outcomes | High |
| Elevated fasting proinsulin predicts progression from normal glucose to type 2 diabetes | Prospective cohort studies (IRAS, Botnia Study) | Elevated proinsulin = increased risk | Moderate to High |
| Proinsulin-to-insulin ratio above 0.2 indicates beta-cell processing stress | Cross-sectional and cohort data; mechanistic studies | Elevated ratio = processing failure | Moderate |
| C-peptide has direct biological effects (renal, neural protection) | Small human trials, animal studies, in vitro | Potentially positive; inconsistent | Low |
| Proinsulin alone reliably diagnoses insulinoma without c-peptide | Case series, guideline expert opinion | Supportive but not sufficient alone | Low to Moderate |
| Fasting c-peptide predicts cardiovascular risk independently of insulin | Some cohort data, not replicated uniformly | Weakly positive | Low |
When Should You Measure Proinsulin vs C-Peptide?
Measure c-peptide when you need to know secretory capacity. The most validated indications are: classifying diabetes type (especially in ambiguous adult-onset cases), assessing residual beta-cell function in established type 1 diabetes, guiding insulin therapy adjustments, and evaluating hypoglycemia during a supervised 72-hour fast.
Measure proinsulin when you need to assess processing quality. The most validated indications are: early risk stratification in prediabetes or metabolic syndrome, research into beta-cell stress, and the workup of suspected insulinoma (where proinsulin above 5 pmol/L during fasting hypoglycemia is a recognized diagnostic criterion in Endocrine Society guidelines).
Measure both together when the clinical question is whether declining beta-cell function reflects reduced mass (low c-peptide) or impaired processing efficiency (disproportionately high proinsulin with still-adequate total c-peptide). These represent different pathophysiological stages and different management implications.
Honest Head-to-Head Comparison Table
| Feature | C-Peptide | Proinsulin |
|---|---|---|
| Primary clinical use | Quantify beta-cell secretory capacity | Detect early beta-cell processing stress |
| Half-life in plasma | Roughly 20 to 31 minutes | Roughly 17 to 30 minutes (varies by fragment) |
| Hepatic first-pass extraction | Less than 10 percent | Low, similar to c-peptide |
| Cross-reactivity with exogenous insulin | None; ideal for monitoring injected insulin users | None |
| Renal clearance effect | Rises significantly in renal impairment; interpret with caution | Also retained in renal impairment |
| Diagnostic guideline inclusion | ADA, Endocrine Society, TrialNet, ISPAD | Endocrine Society (insulinoma); research guidelines |
| Assay availability | Widely available, most clinical labs | Specialty/reference labs; not universally available |
| Cost | Moderate; often covered by insurance for diabetes classification | Higher; often not covered outside insulinoma workup |
| Where c-peptide loses | Does not detect early processing failure when total secretion is still normal | Proinsulin wins for early pre-diabetic risk stratification |
| Where proinsulin loses | Not validated for diabetes classification, residual function, or insulin dosing | C-peptide wins for all standard clinical diabetes management |
What Most Pages Get Wrong About These Two Markers
They treat c-peptide as a direct proxy for insulin. It is not. C-peptide and insulin are secreted equimolarly from the pancreas, but peripheral concentrations diverge because insulin is cleared 50 to 80 percent by the liver on first pass while c-peptide is not. C-peptide reflects total pancreatic output; peripheral insulin reflects what escapes hepatic extraction. In insulin-resistant states with increased hepatic insulin clearance, peripheral insulin can be paradoxically low even when total secretion is high. C-peptide correctly captures this; peripheral insulin does not.
They ignore assay incompatibility. Early c-peptide assays using polyclonal antibodies cross-reacted with proinsulin and split proinsulin, inflating c-peptide readings by a variable and unpredictable amount. Modern two-site immunometric assays are more specific, but calibration still differs between platforms (Roche Elecsys, Abbott Architect, Siemens Centaur). A result of 0.6 nmol/L on one platform does not equal 0.6 nmol/L on another. This matters clinically when a patient switches reference labs.
They omit renal confounding. Because both c-peptide and proinsulin are predominantly renally cleared, any degree of chronic kidney disease elevates both markers independently of beta-cell function. An eGFR below roughly 60 mL/min/1.73m2 can more than double fasting c-peptide. Interpreting a c-peptide of 1.2 nmol/L in a patient with stage 3 CKD as evidence of adequate beta-cell function is a common and potentially harmful error.
They conflate proinsulin measurement with proinsulin therapy. No approved therapeutic use of exogenous proinsulin exists in the United States. Proinsulin is a diagnostic biomarker, not a peptide supplement or therapeutic compound.
Why Assay Cross-Reactivity Changes Your Interpretation
Proinsulin contains the complete amino acid sequences of both the insulin B-chain and A-chain connected by the c-peptide segment. Antibodies raised against c-peptide or insulin epitopes therefore have inherent risk of cross-reacting with intact proinsulin or its split forms.
In a polyclonal c-peptide immunoassay, the antibody pool may include clones that bind the c-peptide region within intact proinsulin. Because proinsulin is larger and present in the sample, it competes with or augments the signal depending on assay architecture. The result: c-peptide appears higher than the true molar concentration of free c-peptide. In patients with disproportionate hyperproinsulinemia (such as early type 2 diabetes), this artifact is largest exactly when accurate c-peptide measurement matters most.
Two-site sandwich immunometric assays use two antibodies targeting spatially separated epitopes. If one epitope is c-peptide-specific and one is blocked in the proinsulin conformation, cross-reactivity is reduced. The Diabetes Research in Children Network and TrialNet trials standardized their c-peptide assays to a WHO international standard (IS 84/510) to enable cross-study comparison. If a lab report does not state which standard its calibration is traceable to, longitudinal trending is unreliable.
Operational and Label Literacy: Reading a Lab Report Correctly
C-peptide units: Results appear in nmol/L or ng/mL depending on the laboratory. The conversion is 1 nmol/L = approximately 3.0 ng/mL (using a molecular weight of approximately 3,020 Da for human c-peptide). Always confirm which unit is reported before applying a reference range.
Fasting vs stimulated: A fasting c-peptide below 0.1 nmol/L with hyperglycemia indicates severe insulin deficiency. A stimulated c-peptide (90 minutes after a mixed meal or glucagon 1 mg IV) is more sensitive for detecting small residual function. The TrialNet threshold of 0.2 nmol/L stimulated is a published research endpoint, not a universal clinical action point.
Proinsulin reference ranges: Most assays report intact proinsulin. Reference intervals are assay-specific. A commonly cited upper limit for fasting intact proinsulin is 11 pmol/L, but confirm the reference interval for the specific assay platform used. Des-31,32 split proinsulin and des-64,65 split proinsulin are measured separately on some research panels and are not interchangeable with intact proinsulin values.
What a degraded or improperly collected sample looks like: Both proinsulin and c-peptide require prompt centrifugation and chilled transport. Samples left at room temperature degrade proinsulin faster than c-peptide (proinsulin is more protease-sensitive due to exposed cleavage sites). A sample showing implausibly low proinsulin with normal c-peptide, especially if the proinsulin-to-c-peptide ratio is near zero, may reflect pre-analytical degradation. Confirm with a repeat draw if clinically important.
Calculating the proinsulin-to-insulin ratio: Convert both to pmol/L (insulin: 1 uU/mL = 6.0 pmol/L using the WHO 86/500 standard). Divide proinsulin (pmol/L) by insulin (pmol/L). A ratio above 0.2 is the commonly cited threshold for disproportionate hyperproinsulinemia. Note that the ratio is meaningless if fasting insulin is suppressed to very low levels, as small absolute proinsulin values will produce an artificially high ratio.
Frequently Asked Questions
What is the difference between proinsulin and c-peptide?
Proinsulin is the single-chain precursor protein that folds into insulin and c-peptide before cleavage. C-peptide is the connecting peptide released in equimolar amounts with insulin. C-peptide reflects total beta-cell secretion; proinsulin reflects processing efficiency and ER stress.
Which is a better marker of insulin resistance, proinsulin or c-peptide?
Fasting proinsulin and the proinsulin-to-insulin ratio are considered more specific early markers of beta-cell dysfunction than fasting c-peptide alone, because elevated proinsulin reflects impaired granule processing before insulin secretion itself falls.
Does c-peptide measure the same thing as insulin?
C-peptide and insulin are released in roughly equimolar amounts, but c-peptide has a longer half-life (roughly 20 to 30 minutes vs 3 to 5 minutes for insulin) and is not cleared by the liver on first pass, making it a more stable index of total beta-cell output.
What is a normal fasting proinsulin level?
Fasting intact proinsulin below roughly 11 pmol/L is generally considered normal in most immunoassay reference ranges, though exact cutoffs vary by assay. A proinsulin-to-insulin molar ratio above 0.2 is frequently cited as a threshold for impaired processing.
What is a normal fasting c-peptide level?
Most laboratories report fasting c-peptide reference ranges of approximately 0.5 to 2.0 nmol/L (roughly 1.5 to 6 ng/mL), though ranges differ between assays. Stimulated c-peptide above 0.2 nmol/L typically indicates clinically meaningful residual beta-cell function.
Why is c-peptide measured in type 1 diabetes?
C-peptide quantifies residual beta-cell mass in type 1 diabetes because injected insulin does not produce c-peptide. Even small residual c-peptide levels (above roughly 0.2 nmol/L) correlate with better glycemic control and lower hypoglycemia risk.
Can proinsulin be elevated in type 2 diabetes?
Yes. Disproportionate hyperproinsulinemia, where proinsulin represents more than 20 to 25 percent of total insulin-like immunoreactivity, is a consistent finding in type 2 diabetes and appears before overt hyperglycemia in high-risk individuals.
Is proinsulin or c-peptide better for diagnosing insulinoma?
Both are used. During a supervised 72-hour fast, a proinsulin level above 5 pmol/L in the context of hypoglycemia strongly supports insulinoma. C-peptide above 0.2 nmol/L during hypoglycemia confirms endogenous insulin production. Current Endocrine Society guidelines include both in the diagnostic criteria.
Do exogenous peptide supplements affect proinsulin or c-peptide levels?
Oral peptide supplements do not directly raise proinsulin or c-peptide because these are endogenous markers of pancreatic beta-cell function, not exogenous peptides. Injectable insulin secretagogues can raise c-peptide as a downstream effect of stimulating beta cells.
What does a low c-peptide with high blood glucose mean?
Low or undetectable c-peptide with hyperglycemia points to absolute insulin deficiency, consistent with type 1 diabetes, late-stage type 2 diabetes with beta-cell exhaustion, or pancreatogenic diabetes. It distinguishes these from insulin resistance states where c-peptide is typically normal or elevated.
Why does the proinsulin-to-c-peptide ratio matter clinically?
The molar ratio of proinsulin to c-peptide (or to insulin) reflects how efficiently beta cells convert proinsulin to mature insulin. A rising ratio is a sensitive early sign of beta-cell stress that can precede changes in fasting glucose or HbA1c by years.
Sources
- Haffner SM, Mykkanen L, Valdez RA, et al. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J Clin Endocrinol Metab. 1994;79(6):1806-1810.
- Ward WK, LaCava EC, Paquette TL, et al. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia. 1987;30(9):698-702.
- Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al. Mixed meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care. 2008;31(10):1966-1971.
- Sacks DB (Ed). Insulin, proinsulin, and c-peptide. In: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 5th ed. Elsevier, 2012.
- Loopstra-Masters RC, Haffner SM, Lorenzo C, et al. Proinsulin-to-c-peptide ratio vs proinsulin-to-insulin ratio in the prediction of incident diabetes. Diabetologia. 2011;54(12):3047-3054.
- Endocrine Society Clinical Practice Guideline: Diagnosis and Treatment of Hypoglycemic Disorders. J Clin Endocrinol Metab. 2009;94(3):709-728.
- Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function. Diabetes. 2004;53(1):250-264.
- TrialNet Study Group. C-peptide as a primary outcome in type 1 diabetes clinical trials. Multiple publications 2009 to 2023. Available at clinicaltrials.gov (TrialNet).
- Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev. 1998;19(5):608-624.
- Jones AG, Hattersley AT. The clinical utility of c-peptide measurement in the care of patients with diabetes. Diabet Med. 2013;30(7):803-817.
- Koskinen P, Voutilainen E, Koskinen T, Viikari J. Immunoreactive proinsulin and c-peptide. Clin Chim Acta. 1986;154(2-3):83-92.
- American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. Updated annually. Section on Classification and Diagnosis.
Footer Disclaimers
Platform: FormBlends provides educational and informational content only. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before making any clinical or therapeutic decision.
Research Compound or Compounded Medication: Proinsulin and c-peptide as discussed on this page are endogenous biomarkers measured in diagnostic laboratory assays. They are not approved therapeutic drugs, dietary supplements, or compounded medications. No FormBlends product claim is made on this page.
Results: Individual laboratory values and clinical outcomes vary depending on assay platform, sample handling, patient physiology, and clinical context. Reference ranges cited are representative and not universally applicable to every laboratory or population.
Trademark: All product and assay names mentioned are the property of their respective owners. FormBlends has no affiliation with TrialNet, the Endocrine Society, or any diagnostic manufacturer mentioned herein.